ClinicalTrials.gg
Not yet recruitingNCT05525715Updated Sep 2, 2022

A Study of QY201 Tablet in Subjects With Moderate to Severe Atopic Dermatitis

A Phase 1/2 interventional study of 2mg QY201 tablets or 2mg QY201 placebo,BID and 5mg QY201 tablets or 5mg QY201 placebo,BID in Atopic Dermatitis, sponsored by E-nitiate Biopharmaceuticals (Hangzhou) Co., Ltd.. Not yet recruiting. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2022-09-02.

Sponsored by E-nitiate Biopharmaceuticals (Hangzhou) Co., Ltd. · Phase 1/2, Interventional, and Treatment

From the registry’s dates

  • Primary completion was expected by Dec 2025, 11 months ago, but the record still lists the study as not yet recruiting.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1/2
Study type
Interventional
Enrollment
260
Allocation
Randomized
Ages
18 Years to 75 Years
Sex
All
01

Study summary

This is a phase Ib/II, randomized, double-blind, placebo-controlled, parallel, multicenter study of a certain phase to evaluate the efficacy, safety, and pharmacokinetic characteristics of QY201 tablet in subjects in moderate to severe atopic dermatitis

02

Conditions studied

  • Atopic Dermatitis

Browse trials for

03

In context

Dermatitis, Atopic

1,594 studies on the registry are indexed under Dermatitis, Atopic; 287 are open to participants now.

This study's planned enrollment of 260 is above the median of 82 across 1,248 interventional studies indexed under Dermatitis, Atopic.

Browse Dermatitis, Atopic studies →

Lead sponsor

E-nitiate Biopharmaceuticals (Hangzhou) Co., Ltd. is the lead sponsor of 7 studies on the registry; 4 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Having been informed the purpose, nature, methods and possible adverse reactions of the trial, the subjects agreed to be subjects and sign an form before the start of any research process.
  2. Part1(Phase Ⅰb):Male and female subjects aged 18 to 65 (including 18 and 45).Part2(Phase Ⅱ):Male and female subjects aged 18 to 75 (including 18 and 45).
  3. Atopic dermatitis with a diagnosis confirmed by a dermatologist (according to the Hanifin and Rajka criteria); and also onset of symptoms at least 6 month prior to screening visit.
  4. Moderate to severe atopic dermatitis defined by an IGA score ≥ 3,an EASI ≥ 16, an PP-NRS≥4, and an BSA ≥ 10% at the screening and baseline visit.
  5. Documented history (within 6 mouths prior to the screening visit) of inadequate or medically inadvisable response to topical (TCS), topical calcineurin inhibitors (TCI), systematic treatment or phototherapy.
  6. Twice daily use of an stable-dose, additive-free, bland emollient for at least 7 days prior to Day 1, and continued for the duration of this trial.
  7. Communicate well with investigators, understand and abide by requirements of this trial.

Exclusion criteria

Exclusion Criteria:

  1. Have evidence of active or latent or inadequately treated infection with mycobacterium tuberculosis (TB) as defined by investigators or specialist physicians according to history, symptoms, signs, laboratory tests, T-SPOT test,and imagings, unless subjects had previously received an adequate course of therapy at least 1 month.
  2. History of mental disorders, genetic history of mental disorder, or epilepsy treated by antipsychotics and sedatives.
  3. In addition to AD, subjects who have current or recent history of severe immunologic/rheumatologic, cardiovascular, hepatic, renal, gastrointestinal, or neurologic disease, or have a history of with the exception of adequately treated or excised non- basal cell or squamous cell cancer of the skin or cervical carcinoma in situ that might need systematic hormone therapy or other interventions, may increase the risk defined by investigators.
  4. In addition to AD, subjects have other dermatoses that affect the evaluation of trial results, or have a wide range of tattoos, birthmarks, skin scars in the skin lesion area.
  5. Have a known immunodeficiency disorder or a first-degree relative with a hereditary immunodeficiency.
  6. Subjects who have received or are planning to receive an organ transplant operation and are taking , such as liver or kidney transplantation.
  7. Any of the following abnormalities:

    1. Within 3 months, subjects who have acute myocardial infarction, unstable angina pectoris, coronary artery bypass grafting, or coronary stent implantation prior to Day 1;
    2. Have a history of severe arrhythmias, such as (Grade II type 2 or III ATV block, long syndrome, or QTcF abnormalities: >470 ms in men and >480 ms in women);
    3. Decompensated cardiac insufficiency ( Class III or IV);
    4. Other cardiac conditions that required treatment and are ineligible for the study according to the investigator.
  8. Infected with various viruses. For , subjects who are Hepatitis B Surface Antigen (HBsAg) or Hepatitis B Core Antibody (HBcAb) positive, and HBV-DNA positive are not eligible for the study. For , subjects who are HCV antibody positive is excluded. Subjects who are Human Immunodeficiency Viruses antibody or Treponema pallidum antibody positive are also not eligible for the study.
  9. Presence of any of the following laboratory abnormalities at the screening visit:

    1. Part 1 (Phase Ⅰb):

      Fasting blood glucose> (ULN);Hypertension poorly controlled by medication (Systolic pressure≥150mmHg, Diastolic pressure≥95mmHg);WBC, Neutrophils, Lymphocyte count, count or \<lower limits of normal (LLN);Serum creatinine>ULN or \<60 mL/min;Total , or ALT values>ULN;PT or values>ULN;

    2. Part 2 (Phase Ⅱ):

    Fasting blood glucose poorly controlled>10 mmol/L;Hypertension poorly controlled by medication (Systolic pressure≥160mmHg, Diastolic pressure≥100mmHg);WBC\<3.0×109/L, Neutrophils\<1.5×109/L; Lymphocyte count\<0.8×109/L, Platelet count\<100.0×109/L and Hemoglobin\<100 g/L;Serum creatinine>1.5 times the ULN or eGFR\<40 mL/min;Total bilirubin>1.5 times the ULN, AST or ALT values>2 times the ULN;PT or APTT values>1.5 times the ULN.

  10. Have a clinical symptomatic infection requiring antimicrobial therapy, such as bacteria, viruses, parasites or fungi during screening.
  11. Have a history (single episode) of disseminated herpes zoster or disseminated herpes simplex, or a recurrent (more than one episode ) of localized, dermatomal herpes zoster.
  12. Have a history of cerebral hemorrhage or cerebral infarction within 1 years prior to Day 1.
  13. Have a history of alcohol or substance abuse within 6 months prior to Day 1.
  14. Have a history of hemorrhage (more than 400 mL), such as trauma, blood collection or donation, or have a plan of blood donation during or after the study.
  15. Have been treated by JAK inhibitors, such as Ruxolitinib, Tofacitinib, Baricitinib, Filgotinib, Lestaurtinib, Pacritinib, Delgocitinib, Upadacitinib, or Abrocitinib, within 3 months prior to Day 1.
  16. Have been treated by biologicals of AD, such as Dupilumab, within 8 weeks or 5 half-live prior to Day 1, whichever is longer.
  17. Have received grade 3 or 4 surgery within 8 weeks prior to Day 1.
  18. Have been vaccinated with live or attenuated within 4 weeks prior to Day 1.
  19. Prior to Day 1, have joined any clinical trial of drug within 4 weeks (or 5 half-life periods, depending on the longer one), or any clinical trial of medical apparatus and instruments within 3 months.
  20. Have been treated by any long-acting anticoagulant drugs, such as Warfarin, Clopidogrel, or subjects who require continuous anticoagulant therapy, except for Aspirin≤100 mg per day.
  21. Have a history of oral immune suppressants (eg, systemic , cyclosporine A [CsA], mycophenolate-mofetil [MMF], interferon-γ [IFN-γ], azathioprine, methotrexate) or Phototherapy (eg, UVB or PUVA) within 4 weeks or within 5 half-lives (if known) prior to Day 1, whichever is longer.
  22. Have received topical treatments that could affect atopic dermatitis (eg, corticosteroids (TCS), calcineurin inhibitors (TCI), or PDE-4 inhibitors) within 2 weeks prior to Day 1.
  23. Have received strong inhibitors or inducers of Hepatic metabolic enzymes.
  24. Subjects who are unable to take tablets, allergic to the active ingredient or of the drug.
  25. In the opinion of the investigator, subjects have a history of gastrointestinal diseases that will affect the absorption of oral drugs, such as gastrointestinal perforation.
  26. Pregnant female subjects, breastfeeding female subjects, or male subjects able to father children and female subjects of who are unwilling or unable to use a highly effective method of as outlined in this protocol for the duration of the study and for at least 6 months after last use of investigational drug.
  27. Subjects who are unavoidable to or plan exposure to natural or artificial ultraviolet (UV) radiation which could affect atopic dermatitis in the opinion of the investigator.
  28. In the opinion of the investigator, subjects who are not suitable to participate in this clinical study.
Terms in these criteria, in plain language(23)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

INR, PT and aPTT (clotting tests)

Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.

Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.

Live vaccines

Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.

CYP3A (CYP3A4) inhibitors and inducers

CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.

Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

05

Study design

Phase
Phase 1 / Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Investigator, Outcomes assessor)
Enrollment
260 participants (estimated)

Study arms

  • Experimental
    Phase Ib Cohort 1(2mg QY201 tablets or 2mg QY201 placebo)

    8 subjects use 2mg QY201 tablets,2 subject uses 2mg QY201 placebo ,BID,29 days

    Drug: 2mg QY201 tablets or 2mg QY201 placebo,BID

  • Experimental
    Phase Ib Cohort 2(5mg QY201 tablets or 5mg QY201 placebo)

    8 subjects use 5mg QY201 tablets,2 subject uses 5mg QY201 placebo ,BID,29 days

    Drug: 5mg QY201 tablets or 5mg QY201 placebo,BID

  • Experimental
    Phase Ib Cohort 3(10mg QY201 tablets or 10mg QY201 placebo)

    8 subjects use 10mg QY201 tablets,2 subject uses 10mg QY201 placebo,QD,29 days

    Drug: 10mg QY201 tablets or 10mg QY201 placebo,QD

  • Experimental
    Phase Ib Cohort 4(10mg QY201 tablets or 10mg QY201 placebo)

    8 subjects use 10mg QY201 tablets,2 subject uses 10mg QY201 placebo,BID,29 days

    Drug: 10mg QY201 tablets or 10mg QY201 placebo,BID

  • Experimental
    Phase Ib Cohort 5(15mg QY201 tablets or 15mg QY201 placebo)

    8 subjects use 15mg QY201 tablets,2 subject uses 15mg QY201 placebo,BID,29 days

    Drug: 15mg QY201 tablets or 15mg QY201 placebo,BID

  • Experimental
    Phase Ib Cohort 6(20mg QY201 tablets or 20mg QY201 placebo)

    8 subjects use 20mg QY201 tablets,2 subject uses 20mg QY201 placebo,BID,29 days

    Drug: 20mg QY201 tablets or 20mg QY201 placebo,BID

  • Experimental
    Phase II Cohort1 (5mg QY201 tablets)

    50 subjects use 5mg QY201 tablets twice daily for 12 weeks

    Drug: 5mg QY201 tablets,BID

  • Experimental
    Phase II Cohort2 (10mg QY201 tablets)

    50 subjects use 10mg QY201 tablets twice daily for 12 weeks

    Drug: 10mg QY201 tablets,BID

  • Experimental
    Phase II Cohort3 (20mg QY201 tablets)

    50 subjects use 20mg QY201 tablets twice daily for 12 weeks

    Drug: 20mg QY201 tablets,BID

  • Experimental
    Phase II Cohort4 (QY201 placebo)

    50 subjects use QY201 placebo twice daily for 12 weeks

    Drug: QY201 placebo,BID

Interventions

  • Drug2mg QY201 tablets or 2mg QY201 placebo,BID

    2mg QY201 tablets or 2mg QY201 placebo,BID

  • Drug5mg QY201 tablets or 5mg QY201 placebo,BID

    5mg QY201 tablets or 5mg QY201 placebo,BID

  • Drug10mg QY201 tablets or 10mg QY201 placebo,QD

    10mg QY201 tablets or 10mg QY201 placebo,QD

  • Drug10mg QY201 tablets or 10mg QY201 placebo,BID

    10mg QY201 tablets or 10mg QY201 placebo,BID

  • Drug15mg QY201 tablets or 15mg QY201 placebo,BID

    15mg QY201 tablets or 15mg QY201 placebo,BID

  • Drug20mg QY201 tablets or 20mg QY201 placebo,BID

    20mg QY201 tablets or 20mg QY201 placebo,BID

  • Drug5mg QY201 tablets,BID

    5mg QY201 tablets,BID

  • Drug10mg QY201 tablets,BID

    10mg QY201 tablets,BID

  • Drug20mg QY201 tablets,BID

    20mg QY201 tablets,BID

  • DrugQY201 placebo,BID

    QY201placebo,BID

06

What researchers measure

Primary outcomes

  1. Number of Participants With Treatment Emergent Adverse Events (AEs)- Phase Ⅰb

    Number of participants with treatment emergent adverse events (AEs) and change from baseline in vital signs (blood pressure, pulse rate, respiratory rate body temperature), physical examination, ECG parameters, clinical laboratory

    Time frame: From the first administration to 28 days after the last administration of the study drug

  2. Percentage of Participants Achieving >=75% Improvement From Baseline in Eczema Area and Severity Index (EASI75) Response at Week 12- Phase Ⅱ

    EASI quantifies severity of AD based on severity of lesion clinical signs and percentage (%) of body surface area (BSA) affected. Severity of clinical signs of AD lesions (erythema, induration/papulation, excoriation and lichenification) were scored separately for each of 4 body regions (head and neck, upper limbs, trunk and lower limbs ) on a 4-point scale: 0= absent; 1= mild; 2= moderate; 3= severe. EASI area score was based on % BSA with AD in body region: 0 (0%), 1 (0 to 9%), 2 (10 to 29%), 3 (30 to 49%), 4 (50 to 69%), 5 (70 to 89%) and 6 (90 to 100%). Total EASI score =0.1\*Ah\*(Eh+Ih+Exh+Lh) + 0.2\*Au\*(Eu+Iu+ExU+Lu) + 0.3\*At\*(Et+It+Ext+Lt) + 0.4\*Al\*(El+Il+Exl+Ll); A = EASI area score; E = erythema; I = induration/papulation; Ex = excoriation; L = lichenification; h = head and neck; u = upper limbs; t = trunk; l = lower limbs. Total EASI score ranged from 0.0 to 72.0, with higher scores indicating greater severity of AD.

    Time frame: Week 12

Secondary outcomes

  1. Pharmacokinetic parameters-Phase Ib

    Tmax

    Time frame: Day1 to Day 30

  2. Pharmacokinetic parameters-Phase Ib

    Cmax

    Time frame: Day1 to Day 30

  3. Pharmacokinetic parameters-Phase Ib

    t1/2

    Time frame: Day1 to Day 30

  4. Pharmacokinetic parameters-Phase Ib

    AUC0-t

    Time frame: Day1 to Day 30

  5. Pharmacokinetic parameters-Phase Ib

    CL/F

    Time frame: Day1 to Day 30

  6. Pharmacokinetic parameters-Phase Ib

    Vz/F

    Time frame: Day1 to Day 30

  7. Percentage of Participants Achieving >=50%/75%/90% Improvement From Baseline in Eczema Area and Severity Index (EASI-50/EASI-75/EASI-90) Response at Week 2 and 4

    EASI quantifies severity of AD based on severity of lesion clinical signs and percentage (%) of body surface area (BSA) affected. Severity of clinical signs of AD lesions (erythema, induration/papulation, excoriation and lichenification) were scored separately for each of 4 body regions (head and neck, upper limbs, trunk and lower limbs ) on a 4-point scale: 0= absent; 1= mild; 2= moderate; 3= severe. EASI area score was based on % BSA with AD in body region: 0 (0%), 1 (0 to 9%), 2 (10 to 29%), 3 (30 to 49%), 4 (50 to 69%), 5 (70 to 89%) and 6 (90 to 100%). Total EASI score =0.1\*Ah\*(Eh+Ih+Exh+Lh) + 0.2\*Au\*(Eu+Iu+ExU+Lu) + 0.3\*At\*(Et+It+Ext+Lt) + 0.4\*Al\*(El+Il+Exl+Ll); A = EASI area score; E = erythema; I = induration/papulation; Ex = excoriation; L = lichenification; h = head and neck; u = upper limbs; t = trunk; l = lower limbs. Total EASI score ranged from 0.0 to 72.0, with higher scores indicating greater severity of AD.

    Time frame: Week 2 and 4

  8. Number of Participants With Treatment Emergent Adverse Events (AEs)- Phase Ⅱ

    Number of participants with treatment emergent adverse events (AEs) and change from baseline in vital signs (blood pressure, pulse rate, respiratory rate body temperature), physical examination, ECG parameters, clinical laboratory

    Time frame: From the first administration to 28 days after the last administration of the study drug

07

Study locations

No study locations are listed for this record.

08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Oct 2022; primary completion for Dec 2025, 38 months later.

Of 25 industry-sponsored phase 1/2 interventional studies under Dermatitis, Atopic, half reached primary completion within 22 months of starting (the median), counting those still running; a quarter within 8 and three quarters within 38. This study's planned 38 months is above that.

Counting every sponsor, half of 29 studies reached it within 22 months; a quarter within 8 and three quarters within 38.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 28, 2022
First posted
Sep 2, 2022
StartEst.
Oct 2022
Primary completionEst.
Dec 2025
CompletionEst.
Dec 2025
Last update
Sep 2, 2022
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 2, 2022, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05525715
Lead sponsor
E-nitiate Biopharmaceuticals (Hangzhou) Co., Ltd.
Responsible party
Sponsor
First posted
Sep 2, 2022
Start date
Oct 2022 (estimated)
Primary completion
Dec 2025 (estimated)
Completion
Dec 2025 (estimated)
Last update
Sep 2, 2022

Study contacts

LiMing Wu, Ph.D, M.D
Contact
18957118053@163.com
0571- 56007501
LiMing Wu, Ph.D, M.D
principal investigator · Affiliated Hangzhou First People's Hospital of Zhejiang University School of Medicine

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Aug 2022. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion